GlassScriptPhysician profile
Ramona Mihu
NPI 1154614592
$19,269.96
in general payments reported to CMS, 2019-2025
27 companies · $3,948 in 2025
The $3,948 reported for 2025 was more than what 83% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,967 · 2020: $975 · 2021: $1,930 · 2022: $3,677 · 2023: $3,444 · 2024: $3,328 · 2025: $3,948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,720.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,807.80 | 2019-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $3,109.73 | 2019-2025 | |
| Ucb, INC. | $2,622.66 | 2019-2025 | Bimzelx, Cimzia |
| Mallinckrodt Hospital Products INC. | $1,450.43 | 2020-2025 | Acthar |
| Pfizer INC. | $1,160.68 | 2019-2025 | |
| Janssen Biotech, INC. | $976.33 | 2019-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $965.82 | 2019-2024 | Taltz |
| Ani Pharmaceuticals, INC. | $939.13 | 2023-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $850.34 | 2020-2025 | |
| Radius Health, INC. | $707.93 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $620.30 | 2021-2023 | Saphnelo |
| Glaxosmithkline, LLC. | $498.52 | 2019-2025 | Benlysta |
| Horizon Therapeutics Plc | $363.90 | 2019-2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $329.83 | 2019 | |
| Aurinia Pharma U.S., INC. | $226.19 | 2021-2025 | Lupkynis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $170.12 | 2019-2025 | Orencia, Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.78 | 2023-2025 | Cyltezo, Ofev |
| Alvogen INC | $64.82 | 2024-2025 | Teriparatide |
| Fidia Pharma USA INC. | $54.51 | 2023-2024 | Triluron, Hymovis, Hyalgan |
| Tersera Therapeutics LLC | $51.70 | 2024 | Quzyttir |
| Genzyme Corporation | $47.19 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $28.79 | 2024 | Arcalyst |
| Invivyd INC | $28.75 | 2025 | Pemgarda |
| Takeda Pharmaceuticals U.S.A., INC. | $27.47 | 2022 | |
| Genentech USA, INC. | $26.66 | 2019 | |
| Sandoz INC. | $23.90 | 2023 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $18.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramona Mihu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.